NCI Client: Seqirus – Rapivab

NCI Client: Seqirus – Rapivab

NCI introduces client: Seqirus and their anti-viral therapy for influenza – Rapivab®

Rapivab® is indicated for the treatment of acute uncomplicated influenza in patients 2 years and older who have been symptomatic for no more than 2 days.

The Seqirus Anti-Viral Therapy; Rapivab® is a single rapid IV administration that:

  • Reduces morbity and mortality in all patient populations
  • Provides rapid, effective and complete suppression of viral replication
  • Ensures compliance with any optimal safety profile
  • Reduces viral transmission
  • Allows for a wider duration of treatment window (>48 hours)

You can find more information regarding Rapivab® here:

Please see these case studies for effective real life applications.

NCI is excited to introduce this effective solution that can greatly improve the treatment of influenza.

Share this post

Schedule FREE Webinar